About eGenesis
eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company’s proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered porcine kidney, is the Company’s lead program and is currently being evaluated in a multi-patient Expanded Access study at MGH. eGenesis is headquartered in Cambridge, MA.
The Lead Clinical Research Associate is responsible for leading site monitoring activities and providing oversight to CRAs for assigned clinical trials. The Lead CRA works closely with Clinical Operations leadership and cross-functional teams to ensure that studies are conducted according to protocol, ICH-GCP guidelines, regulatory requirements, and company SOPs.